Table 3.
Characteristics of the HCTs in the two cohorts of allogeneic HCT.
| Study group | 2004–2008 N = 87 |
2012–2022 N = 214 |
|---|---|---|
| Age at HCT, years, median (IQR) | 7 (2.3–11) | 7.9 (3.3–13.6) |
| Donor type, n (%) | - | - |
| AD | 70 (80) | 86 (40.2) |
| HAPLO αβ/CD19 depleted | - | 46 (21.5) |
| RD | 17 (20) | 43 (20.1) |
| HAPLO PTCy | - | 39 (18.2) |
| Source of stem-cell graft, n (%) | - | - |
| BM | 67 (78) | 140 (65.4) |
| PBSC | 10 (11) | 63 (29.4) |
| CB | 10 (11) | 11 (5.2) |
| Conditioning regimen, n (%) | - | - |
| MAC | 59 (68) | 157 (73.4) |
| RIC | 28 (32) | 57 (26.6) |
HCT, hematopoietic cell transplantation; D, donor; R, recipient; AD, alternative donor; Haplo, haploidentical related donor; PTCy, post-transplant cyclophosphamide; RD, related donor; Anti-TNF, anti-tumor necrosis factor; MPD, methylprednisolone; aGvHD, acute graft versus host disease; cGvHD, chronic graft versus host disease; BM, bone marrow; PBSC, peripheral blood stem cell; CB, cord blood; MAC, myeloablative conditioning regimen; RIC, reduced intensity conditioning regimen.